FDA Alerts

The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.

The FDA has approved new options for schizophrenia and non-small cell lung cancer, as well as a cerebrospinal fluid test for the detection of various pathogens.

The FDA has approved 2 new drugs for the improvement of blood glucose control in patients with type 1 and type 2 diabetes mellitus.

The FDA has approved a new drug for colorectal cancer, a new test for influenza, and issued a warning of dose confusion with a combination antibacterial drug.

<p>What the Food and Drug Administration calls a 'breakthrough' drug is often not the same as what a layperson would call a breakthrough, a new study shows.</p>

The FDA has approved a drug already indicated for COPD treatment for the long-term, once-daily maintenance of asthma in individuals 12 years old and older.

The FDA has changed the requirements for prescribing, dispensing, and receiving a certain schizophrenia medication due to growing concerns of the risk of neutropenia.

The FDA has approved new options for hidradenitis suppurativa and hereditary orotic acuduria.

The FDA has warned of severe, disabling joint pain associated with the use of certain common diabetes drugs.

The FDA has approved new options for the treatment of type 2 diabetes and hypercholesterolemia, as well as a new continuous glucose monitoring system.